论文信息 - Clostridium difficile infection associated with bismuth-based quadruple therapy (Pylera®) for Helicobacter pylori eradication - 字舞流文

Clostridium difficile infection associated with bismuth-based quadruple therapy (Pylera®) for Helicobacter pylori eradication

M. Castro-Fernández | L. Grande-Santamaría | M. Castro‐Fernández | Alberto Marqués-Ruiz | Sergio Cámara-Baena

[1] R. Hunt,et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[2] A. Sîngeap,et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. , 2013, World journal of gastroenterology.

[3] P. Malfertheiner,et al. Influence of anti‐Helicobacter triple‐therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora , 2001, Alimentary pharmacology & therapeutics.

[4] I. Mohammed,et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection , 1998, American Journal of Gastroenterology.

[5] Archimandritis,et al. Clostridium difficile colitis associated with a ‘triple’ regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori , 1998, Journal of internal medicine.